Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,462

Document Document Title
WO/2021/060336A1
Provided are a novel crosslinked alginic acid, a crosslinked alginic acid structure, etc., by performing a crosslinking reaction using alginic acid derivatives represented by formula (I) and formula (II). As a result, a novel crosslinked...  
WO/2021/055636A1
A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel ...  
WO/2021/051778A1
A disulfide bond-linked hyaluronic acid gel for preventing tissue adhesion after abdominal or pelvic cavity surgery and a preparation method therefor. The content of the disulfide bond-linked hyaluronic acid of the disulfide bond-linked ...  
WO/2021/048595A1
The disclosure relates to methods of preventing an human virus-associated disorder, in particular EBV-associated disorder, as well as to a method of controlling EBV load in a subject, in particular in a subject being at risk of developin...  
WO/2021/013714A1
The invention relates to a composition comprising Mesna for use in a method of surgery. The invention also relates to a method for producing a composition comprising Mesna for use in a method of surgery, to a kit for obtaining a composit...  
WO/2021/013713A1
The invention relates to a composition comprising Mesna, wherein the composition further comprises one or more dyes. The invention also relates to said composition for use in a method of surgery, a kit comprising Mesna and a method for v...  
WO/2020/242424A3
The present invention relates to a glycerol and sodium pentaborate based formulation developed for preventing postoperative adhesions occurring between the manipulated tissues and organs. The objective of the present invention is to prov...  
WO/2020/237323A1
Compositions and methods for the preparation of a subject for fecal microbiota transplantation, in particular for the removal of biofilm material from the colon of a subject, are provided. The provided compositions contain soaps, such as...  
WO/2020/232540A1
A method of reducing or limiting tissue adhesion comprises contacting the tissue with an effective amount of a hydrogel composition comprising: 2% to 6% by weight hyaluronan, and 3% to 18% by weight methylcellulose, wherein the combined ...  
WO/2020/229761A1
The invention relates to a pharmaceutical composition, comprising at least one compound of the echinocandin family and at least one other therapeutically active ingredient except for hypouricemic compounds, intended to be used as a cytop...  
WO/2020/163601A3
In one aspect, methods are described herein employing particle compositions operable to form composite membrane for inhibition of post-surgical adhesions. Briefly, a method of treating a surgical site comprises contacting the surgical si...  
WO/2020/204507A1
The present invention relates to a composition for healing after rotator cuff repair, and more specifically, to a composition comprising teriparatide as an effective component for healing suture tears after rotator cuff repair. The compo...  
WO/2020/173484A1
Disclosed are an anterior chamber perfusate for intraocular surgery and a use thereof; under the effect of balanced intraocular pressure, also containing a certain amount of L-alanyl-L-glutamine. Extracapsular cataract extraction, intrao...  
WO/2020/162580A1
The present invention relates to a pharmaceutical composition containing mesenchymal stem cells to be administered to a patient who has undergone stent implantation. Specifically, the present invention relates to: a pharmaceutical compos...  
WO/2020/144378A1
The present invention relates to the use of SGLT-2 inhibitors and/or an interleukin- 1-receptor antagonist or a non-agonist antibody reactive to IL-1 or IL-1R in the treatment of prevention of symptomatic hypoglycaemia after bariatric su...  
WO/2020/121290A1
Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 μΜ to 1 mM; and (ii)...  
WO/2020/121289A1
Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of between about 5 mg/ml to about 30 mg/ml, and having a total protein conc...  
WO/2020/087181A1
Disclosed herein are matrices, compositions and methods of making matrices. The matrix comprises a biomolecule and the matrix is a dried, cross-linked foam. The matrix is not lyophilized. The method comprises foaming the composition, cro...  
WO/2020/081817A1
The present disclosure includes composite microparticles for magnetically triggered release of a biologically active agent. Also included are systems including the biocompatible composite microparticles and an alternating current (AC) ma...  
WO/2020/067439A1
The purpose of the present invention is to provide: a method for producing a high-quality graft, such as a sheet-shaped cell culture, that includes a variety of iPS cell-derived cells, such as cardiomyocytes, while possessing the functio...  
WO/2020/027686A1
This invention relates to experimental medicine, and specifically to experimental gastroenterology, and may be used to prevent entero-entero anastomotic leaks. A method of preventing entero-entero anastomotic leaks comprising action usin...  
WO/2020/019080A1
Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan composit...  
WO/2020/019077A1
Low endotoxin fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2, 0.18, 0.1, 0.01, 0.001, or 0.0005 endotoxin units (EU) per milligram of the fucan are di...  
WO/2020/019081A1
A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose...  
WO/2020/019078A1
High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60 % w/w of th...  
WO/2020/019079A1
Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan composit...  
WO/2019/227122A8
A method of enhancing embryo implantation in a subject is disclosed which comprises administering to the uterine cavity of the subject a formulation comprising copper and/or zinc in an amount effective to stimulate endometrial production...  
WO/2020/005785A1
The subject invention provides materials and methods for reducing the amount of bioavailable pyrogens in a subject's body. Advantageously, by applying a composition comprising chlorhexidine gluconate to a site in a subject's body, for ex...  
WO/2019/227122A1
A method of enhancing embryo implantation in a subject is disclosed which comprises administering to the uterine cavity of the subject a formulation comprising copper and/or zinc in an amount effective to stimulate endometrial production...  
WO/2019/134725A3
According to the invention, a medicament is disclosed, a.) containing carboxymethylated starch and b.) containing a citrate and/or citric acid for reducing post-operative adhesions.  
WO/2019/153099A1
The invention relates to a compound and procedure for optimising the transplant of vascularised solid organs and reducing the dysfunction of same, which comprises 400 to 1000 mg of alpha lipoic acid (ALA), preferably 600 mg of ALA, and t...  
WO/2019/134725A2
According to the invention, a medicament is disclosed, a.) containing carboxymethylated starch and b.) containing a citrate and/or citric acid for reducing post-operative adhesions.  
WO/2019/135136A1
A bi-coordinated silver (I) complex has antimicrobial activity and general formula Na+ 2[Ag+(L2-)(M2-)], wherein L is a ligand consisting of 2-mercaptobenzoic acid and M is a ligand different from said ligand L and consisting of 2-hydrox...  
WO/2019/135729A1
A composition for aesthetic injections is intended for facial contouring, as well as for improving the condition of mucosa and skin on other parts of the body. The composition for aesthetic injections contains calcium hydroxyapatite and,...  
WO/2019/122157A1
The invention refers to a lyophilisate comprising esmolol, adenosine and at least one pharmaceutical salt and its use in cardioplegia.  
WO/2019/121488A1
The present invention provides nitric oxide releasing hyaluronic acid derivatives of formula (I) in which the carboxylic groups of the hyaluronic acid are partially esterified with a group capable to release nitric oxide: (I) The hyaluro...  
WO/2019/108072A1
In one aspect, the present invention provides a composition comprising zebularine, a nucleotide inhibitor of DNA methyltransferase, optionally in combination with retinoic acid, and said composition for use in promoting complex tissue re...  
WO/2019/078344A1
Post-surgical adhesion at an invasive site and migration of neutrophils to an invasive surgical site are prevented by administering an anti-IL-6 receptor antibody and/or a neutrophil neutralizing antibody.  
WO/2019/078246A1
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as an IDO/TDO inhibitor. The compound represented by formula (I) or a pharmaceutically acceptable salt thereof can, for exam...  
WO/2019/071902A1
Provided is a use of miR-21 in the prepartion of therapeutic drugs or diagnostic reagents for intrauterine adhesion and/or thin endometrium.  
WO/2019/008210A3
The present invention relates to a combined preparation comprising at least a microparticle and a composition, preferably an aqueous pharmaceutical solution, comprising a water-soluble cellulose-derived polymer and hyaluronic acid, prefe...  
WO/2019/016572A1
A compound for use in the treatment or prevention of acute or chronic inflammatory disorders wherein the compound is a compound of Formula 1 : or a salt thereof, wherein n is 2-5, and R1 and R2 are independently selected from H or C1-C4 ...  
WO/2018/231089A1
Field of use: The invention relates to organic and bio-organic combinatorial chemistry, specifically to new combinatorial libraries of polysaccharide derivatives and to supramolecular structures based thereon, which have high biological ...  
WO/2018/217088A1
A staining composition is provided with improved staining intensity. The composition comprises a vital dye and hyaluronic acid, wherein the vital dye comprises Chicago Sky Blue and Trypan Blue. The staining composition is used to stain t...  
WO/2018/217897A1
Disclosed herein is an immunogenic comprising an antigen and optionally IL-12. Also disclosed herein is a method for administering the vaccine through intradermal electroporation.  
WO/2018/200739A1
The present disclosure provides methods and compositions for the treatment and prevention of infections and biofilm prevention during breast augmentation procedures. The present disclosure also provides methods and compositions for the p...  
WO/2018/152592A1
The present disclosure relates to methods and products for reducing adhesions. In certain embodiments, the present disclosure provides a method of reducing adhesions in a subject, the method comprising exposing a region in the subject su...  
WO/2018/144637A1
Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol...  
WO/2018/143115A1
Provided is a bioabsorbable stent that has adequate strength, is highly robust and flexible, and has excellent expandability. This bioabsorbable stent is characterized in that a plurality of first tubular units in which a plurality of su...  
WO/2018/134621A1
A composition for aiding the removal of polyps, in the form of a submucosal injectable formulation, comprising one or more salts of hyaluronic acid, saline solution and indigo carmine, but not including a substance exhibiting an angioton...  

Matches 1 - 50 out of 2,462